Sunwin International Neutraceuticals, Inc. will certainly have the attention of investors this morning. The company has just announced that it now has 500 metric tons of annual high-grade Stevia production capacity, due to newly converted facilities.

The company, a leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world's leading producers of all natural, zero calorie stevia in China, acquired 100% interest of Qufu Shengren in April 2009 and began the conversion of the facilities to produce high grade stevia extracts. The completion of this conversion comes at a time when Sunwin is poised to enter its stevia extracts for use as a sweetener in the U.S. food and beverage industry with the completion of the process for U.S. Food and Drug Administration ("FDA") self-affirmed GRAS status for stevia extracts produced by Sunwin.

Chairman Laiwang Zhang stated, "This additional production is critical as we enter the U.S. markets and build on our strategic partnership with WILD Flavors Inc. Management has been committed to broadening our stevia production capabilities as we jointly develop numerous formulations and products using our stevia extracts that are healthy and great tasting. We have never been more excited about the future prospects for Sunwin and we intend to aggressively pursue the vast opportunities in front of us."

The stock closed yesterday at around Twenty Six cents a share a share.

For an in-depth profile of Sunwin International Neutraceuticals, visit http://wallstreetenews.com/view-company-profiles.php?profile=SUWN_072909.

Pfizer Inc. (NYSE: PFE) down 0.9% on 40.1 million shares traded. Pfizer Inc., founded in 1849, is dedicated to better health and greater access to health care for people and their valued animals.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) up 8.7% on 10.2 million shares traded. BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases.

Merck & Co., Inc. (NYSE: MRK) down 0.5% on 15.2 million shares traded. Merck & Co., Inc.